Remove 2025 Remove Immunization Remove Vaccines
article thumbnail

STAT+: Moderna says data show its combination Covid-flu vaccine generates a strong immune response

STAT

Moderna announced Monday that, in a Phase 3 clinical trial, its combination Covid-19 and influenza vaccine generated stronger immune responses in older adults than individual vaccines that target those viruses. Continue to STAT+ to read the full story…

article thumbnail

APhA 2025: Navigating Current RSV Vaccination Guidelines and Recommendations

Pharmacy Times

Goad, PharmD, MPH, discusses the latest RSV vaccination guidelines and recommendations for 2025, highlighting vaccine options, target populations, timing considerations, evolving CDC policies, and the role of pharmacists in immunization efforts.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Sanofi outlines five-pronged approach to reel in €10B in vaccine sales by 2030

Fierce Pharma

While Dupixent often steals the show, Sanofi isn’t sleeping on its vaccine franchise. | By 2030, Sanofi figures its immunizations could generate more than €10 billion in annual sales, the company said during a vaccines R&D event Thursday.

article thumbnail

UK extends COVID-19 vaccine supply deal with Valneva

pharmaphorum

billion) order for up to 190 million doses of a coronavirus vaccine in development at French company Valneva. The new deal firms up an earlier agreement in principle with the UK in July that covered up to 100 million doses of VLA2001 , a purified inactivated SARS-CoV-2 vaccine that is expected to require a two-dose vaccination regimen.

article thumbnail

Evaxion and ExpreS²ion partner to develop new CMV vaccine

Pharmaceutical Technology

Evaxion Biotech and ExpreS 2 ion Biotechnologies have entered a vaccine discovery collaboration agreement to co-develop a new cytomegalovirus (CMV) vaccine candidate. Until 2025, the companies will equally share the research and intellectual property licensing expenses under the partnership.

article thumbnail

The imperative of fridge-free vaccines

European Pharmaceutical Review

Many of today’s vaccines are produced in ready-to-inject liquid formulations that must be kept cold to maintain stability. However, this greatly complicates both the worldwide distribution and stockpiling of vaccines and other drugs. A requisite cold chain has been designed and implemented to be uninterrupted from factory to patient.

Vaccines 111
article thumbnail

Pharmacy Growth Tricks: Double Your Pharmacy Success in 2025

DiversifyRx

And when you set the right goals, 2025 could be the year you finally break free from PBM madness, build a loyal patient base, and boost your pharmacy profits. For example, if your goal is to grow your immunization program, don’t just say, “I want to do more vaccines.” Better: Hit 750 vaccines by Q4.